NO20065501L - Lxr reseptor modulstorer. - Google Patents

Lxr reseptor modulstorer.

Info

Publication number
NO20065501L
NO20065501L NO20065501A NO20065501A NO20065501L NO 20065501 L NO20065501 L NO 20065501L NO 20065501 A NO20065501 A NO 20065501A NO 20065501 A NO20065501 A NO 20065501A NO 20065501 L NO20065501 L NO 20065501L
Authority
NO
Norway
Prior art keywords
module stores
receptor module
lxr receptor
pharmaceutically acceptable
relates
Prior art date
Application number
NO20065501A
Other languages
English (en)
Inventor
Pierre Dodey
Luc Lebreton
Christine Massardier
Christine Dumas
Philippe Masson
Original Assignee
Fournier Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Sa filed Critical Fournier Lab Sa
Publication of NO20065501L publication Critical patent/NO20065501L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Oppfinnelsen angår forbindelser avledet fra benzensulfonamid-derivatforbindelser med den generelle formel (I) som definert i kravene og farmasøytisk akseptable addisjonssalter derav. Oppfinnelsen angår også en fremgangsmåte for fremstilling av disse, farmasøytisk akseptable preparater inneholdende dem og anvendelse av dem som farmakologisk aktiv substans, ved behandling av neurodegenerative sykdommer, kardiovaskulære sykdommer, inflammatoriske sykdommer og hyperkolesterolemi og diabetes.
NO20065501A 2004-05-07 2006-11-29 Lxr reseptor modulstorer. NO20065501L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0404958A FR2869904B1 (fr) 2004-05-07 2004-05-07 Modulateurs des recepteurs lxr
PCT/FR2005/001139 WO2005121093A1 (fr) 2004-05-07 2005-05-09 Modulateurs des recepteurs lxr

Publications (1)

Publication Number Publication Date
NO20065501L true NO20065501L (no) 2007-01-30

Family

ID=34945760

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065501A NO20065501L (no) 2004-05-07 2006-11-29 Lxr reseptor modulstorer.

Country Status (9)

Country Link
US (1) US7872021B2 (no)
EP (1) EP1742918A1 (no)
JP (1) JP4892475B2 (no)
CN (2) CN102321020A (no)
AU (1) AU2005251979B2 (no)
CA (1) CA2564642A1 (no)
FR (1) FR2869904B1 (no)
NO (1) NO20065501L (no)
WO (1) WO2005121093A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101778831B (zh) * 2007-08-13 2014-08-20 霍夫曼-拉罗奇有限公司 哌嗪酰胺衍生物
US8039493B2 (en) * 2007-09-27 2011-10-18 Hoffmann-La Roche Inc. Biaryl sulfonamide derivatives
BR112013005425A2 (pt) 2010-09-07 2018-05-02 Snu R&Db Foundation compostos sesterterpenos e suas utilizações
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US11746097B2 (en) 2016-06-24 2023-09-05 Saint Louis University LXR inverse agonists for treatment of cancer
EP3568135B1 (en) 2017-01-11 2021-04-07 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
JP7152471B2 (ja) 2017-08-07 2022-10-12 ロダン・セラピューティクス，インコーポレーテッド ヒストン脱アセチル化酵素の二環阻害剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053817A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6559127B1 (en) * 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
WO1999006433A1 (en) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
DE69824037T2 (de) * 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6251932B1 (en) * 1998-09-25 2001-06-26 Asta Medica Ag Immunophilin ligands
US6300341B1 (en) * 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US6855708B2 (en) * 2001-03-20 2005-02-15 Merck & Co., Inc. N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
JP2005022976A (ja) * 2001-07-18 2005-01-27 Ajinomoto Co Inc カルボン酸誘導体
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7560586B2 (en) 2002-03-27 2009-07-14 Smithkline Beecham Corporation Acid and ester compounds and methods of using the same
AU2003223340A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Certain pharmaceutically useful substituted aminoalkyl heterocycles
AU2003228614A1 (en) 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
WO2003090746A1 (en) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
CA2567343A1 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline

Also Published As

Publication number Publication date
JP4892475B2 (ja) 2012-03-07
US20070099960A1 (en) 2007-05-03
EP1742918A1 (fr) 2007-01-17
CN102321020A (zh) 2012-01-18
JP2007536355A (ja) 2007-12-13
CN1950340A (zh) 2007-04-18
CA2564642A1 (fr) 2005-12-22
FR2869904A1 (fr) 2005-11-11
US7872021B2 (en) 2011-01-18
AU2005251979B2 (en) 2012-04-12
FR2869904B1 (fr) 2006-07-28
WO2005121093A1 (fr) 2005-12-22
AU2005251979A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
NO20065501L (no) Lxr reseptor modulstorer.
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
NO20082445L (no) Neuropeptid-2 reseptor-agonister
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200600892A1 (ru) Новые хинолиновые производные
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
NO20090328L (no) Nye forbindelser 385
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20061766L (no) 1,1,1-trifluor-4-fenyl-4-metyl-2-(1H-Pyrrolo'2,3-Cl Pyridin-2-ylmetyl)pentan-2-ol derivater og beslektede forbindelser som glukokortikoidligander for behandling av inflammatoriske sykdommer og diabetes
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20074703L (no) Antibakterielle piperidinderivater
NO20084382L (no) Sykloalkylaminosyrederivater og farmasoytiske sammensetninger derav
NO20074872L (no) Pyrazoler
NO20073664L (no) Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
WO2006024486A3 (en) Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
NO20082496L (no) Pyrazinderivater
NO20070088L (no) 1-, (3R)-amino-4-(2-fluor-fenyl)-butyl !-pyrrolidin-(2R)-karboksylsyre-benzyl amin derivater og beslektede forbindelser som dipeptidyl-peptidase IV (DPP??IV) inhibitorer for behandling av type 2
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application